Copyright
©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Figure 1 Comparison before and after matching in treatment and control groups.
Figure 2 Comparison of recurrence rates between patients who stopped treatment with and without reaching endpoint criteria of the Asian Pacific Association for the Study of the Liver.
APASL: Asian Pacific Association for the Study of the Liver.
Figure 3 Incidence of liver cirrhosis in patients with chronic hepatitis B.
LAM: Lamivudine; CHB: Chronic hepatitis B.
Figure 4 Comparison of incidence of hepatocellular carcinoma in patients with chronic hepatitis B (A) and liver cirrhosis (B) between the lamivudine and control group.
CHB: Chronic hepatitis B; LAM: Lamivudine.
Figure 5 Comparison of death rates between the lamivudine and control group.
LAM: Lamivudine.
- Citation: Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094
- URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13087.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13087